This has led to the development of different myosin-targeting drugs that have reached the clinical trials stage, including the myosin activators omecamtiv mecarbil (OM) (2,3) and danicamtiv (4), and the inhibitors mavacamten (5) and aficamten (6). The gene discussed is MYH14; the disease is ocular melanoma.